Novavax Net Income Applicable To Common Shares from 2010 to 2026
| NVV1 Stock | EUR 7.41 0.03 0.40% |
Net Loss | First Reported 2010-12-31 | Previous Quarter -592.1 M | Current Value -621.8 M | Quarterly Volatility 378.9 M |
Check Novavax financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Novavax's main balance sheet or income statement drivers, such as Interest Expense of 14.1 M, Selling General Administrative of 230.8 M or Total Revenue of 557.2 M, as well as many indicators such as Price To Sales Ratio of 1.96, Dividend Yield of 0.0066 or Days Sales Outstanding of 49.54. Novavax financial statements analysis is a perfect complement when working with Novavax Valuation or Volatility modules.
Novavax | Net Income Applicable To Common Shares |
The Net Income Applicable To Common Shares trend for Novavax offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Novavax is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest Novavax's Net Income Applicable To Common Shares Growth Pattern
Below is the plot of the Net Income Applicable To Common Shares of Novavax over the last few years. It is the net income that remains after preferred dividends have been deducted, available to common shareholders. Novavax's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Novavax's overall financial position and show how it may be relating to other accounts over time.
| Net Income Applicable To Common Shares | 10 Years Trend |
|
Net Income Applicable To Common Shares |
| Timeline |
Novavax Net Income Applicable To Common Shares Regression Statistics
| Arithmetic Mean | (459,452,791) | |
| Coefficient Of Variation | (82.47) | |
| Mean Deviation | 255,852,789 | |
| Median | (279,966,000) | |
| Standard Deviation | 378,896,562 | |
| Sample Variance | 143562.6T | |
| Range | 1.6B | |
| R-Value | (0.50) | |
| Mean Square Error | 115352T | |
| R-Squared | 0.25 | |
| Significance | 0.04 | |
| Slope | (37,269,621) | |
| Total Sum of Squares | 2297001.7T |
Novavax Net Income Applicable To Common Shares History
About Novavax Financial Statements
Novavax stakeholders use historical fundamental indicators, such as Novavax's Net Income Applicable To Common Shares, to determine how well the company is positioned to perform in the future. Although Novavax investors may analyze each financial statement separately, they are all interrelated. For example, changes in Novavax's assets and liabilities are reflected in the revenues and expenses on Novavax's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Novavax. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Loss | -592.1 M | -621.8 M |
Currently Active Assets on Macroaxis
When determining whether Novavax offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Novavax's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Novavax Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Novavax Stock:Check out the analysis of Novavax Correlation against competitors. For more detail on how to invest in Novavax Stock please use our How to Invest in Novavax guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.